Evidence map›Paper›PMID 36031695›Full record

ArticleEuropean journal of medicinal chemistry2022

Development of a PET radioligand for α2δ-1 subunit of calcium channels for imaging neuropathic pain.

Yu-Peng Zhou, Yang Sun, Kazue Takahashi, Vasily Belov, Nick Andrews, Clifford J Woolf, Pedro Brugarolas

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Evaluation ofACS chemical neuroscience · 2023
    Article
  5. Up-and-coming Radiotracers for Imaging Pain Generators.Seminars in musculoskeletal radiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yu-Peng ZhouGordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Yang SunGordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Kazue TakahashiGordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Vasily BelovGordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Nick AndrewsF.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Clifford J WoolfF.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Pedro BrugarolasGordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: pbrugarolas@mgh.harvard.edu.
Harvard University · USBoston Children's Hospital · US

Funding

Unravelling Mechanisms and Novel Therapeutic Targets for Peripheral Neuropathy and Neuropathic Pain (Diversity Supplement)R35NS105076 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI WOOLF, CLIFFORD J · 2018 to 2025
$9.5M
Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI Hisashi Umemori · 2021 to 2026
$9.4M
Development of a PET radioligand for alpha2delta-1 receptors to visualize and quantify neuropathic pain mechanisms neuropathic pain mechanismsR21NS120139 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI BRUGAROLAS, PEDRO · 2020 to 2020
$456k
NICHD NIH HHS P50 HD105351NINDS NIH HHS R21 NS120139NINDS NIH HHS R35 NS105076
6 · The paper itself

Abstract

Neuropathic pain affects 7-10% of the adult population. Being able to accurately monitor biological changes underlying neuropathic pain will improve our understanding of neuropathic pain mechanisms and facilitate the development of novel therapeutics. Positron emission tomography (PET) is a noninvasive molecular imaging technique that can provide quantitative information of biochemical changes at the whole-body level by using radiolabeled ligands. One important biological change underlying the development of neuropathic pain is the overexpression of α2δ-1 subunit of voltage-dependent calcium channels (the target of gabapentin). Thus, we hypothesized that a radiolabeled form of gabapentin may allow imaging changes in α2δ-1 for monitoring the underlying pathophysiology of neuropathic pain. Here, we report the development of two

Indexed as

Calcium Channels, L-TypeNeuralgiaAnimalsGabapentinLigandsPositron-Emission TomographyRatsRats, Sprague-DawleyTomography, X-Ray ComputedCalcium Channels, L-TypeGabapentinLigandsAutoradiographyFluorine-18GabapentinNeuropathic painPETRadiotracerSARSpinal nerve ligation

Identifiers

PMID36031695
PMCPMC9623503
OpenAlexW4292254878

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.